** Shares of CSL CSL.AX fall as much as 5.5% to A$255.4, their lowest levels since November 21, 2023
** The biopharmaceutical co has reported half-year net profit of $2.01 billion, lower than analysts' forecast of $2.09 billion
** Co says earnings weighed down by falling immunisation rates in the U.S., its largest market
** About 1.2 million shares change hands, vs the 30-day average of 558,040
** Stock fell 1.8% in 2024
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.